Now showing items 2216-2235 of 3824

    • Molecular mechanisms of Bdp1 in TFIIIB assembly and RNA polymerase III transcription initiation. 

      Gouge, J; Guthertz, N; Kramm, K; Dergai, O; Abascal-Palacios, G; Satia, K; Cousin, P; Hernandez, N; Grohmann, D; Vannini, A (2017-07-25)
      Initiation of gene transcription by RNA polymerase (Pol) III requires the activity of TFIIIB, a complex formed by Brf1 (or Brf2), TBP (TATA-binding protein), and Bdp1. TFIIIB is required for recruitment of Pol III and to ...
    • Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. 

      Galluzzi, L; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Agostinis, P; Alnemri, ES; Altucci, L; Amelio, I; Andrews, DW; Annicchiarico-Petruzzelli, M; Antonov, AV; Arama, E; Baehrecke, EH; Barlev, NA; Bazan, NG; Bernassola, F; Bertrand, MJM; Bianchi, K; Blagosklonny, MV; Blomgren, K; Borner, C; Boya, P; Brenner, C; Campanella, M; Candi, E; Carmona-Gutierrez, D; Cecconi, F; Chan, FK-M; Chandel, NS; Cheng, EH; Chipuk, JE; Cidlowski, JA; Ciechanover, A; Cohen, GM; Conrad, M; Cubillos-Ruiz, JR; Czabotar, PE; D'Angiolella, V; Dawson, TM; Dawson, VL; De Laurenzi, V; De Maria, R; Debatin, K-M; DeBerardinis, RJ; Deshmukh, M; Di Daniele, N; Di Virgilio, F; Dixit, VM; Dixon, SJ; Duckett, CS; Dynlacht, BD; El-Deiry, WS; Elrod, JW; Fimia, GM; Fulda, S; García-Sáez, AJ; Garg, AD; Garrido, C; Gavathiotis, E; Golstein, P; Gottlieb, E; Green, DR; Greene, LA; Gronemeyer, H; Gross, A; Hajnoczky, G; Hardwick, JM; Harris, IS; Hengartner, MO; Hetz, C; Ichijo, H; Jäättelä, M; Joseph, B; Jost, PJ; Juin, PP; Kaiser, WJ; Karin, M; Kaufmann, T; Kepp, O; Kimchi, A; Kitsis, RN; Klionsky, DJ; Knight, RA; Kumar, S; Lee, SW; Lemasters, JJ; Levine, B; Linkermann, A; Lipton, SA; Lockshin, RA; López-Otín, C; Lowe, SW; Luedde, T; Lugli, E; MacFarlane, M; Madeo, F; Malewicz, M; Malorni, W; Manic, G; Marine, J-C; Martin, SJ; Martinou, J-C; Medema, JP; Mehlen, P; Meier, P; Melino, S; Miao, EA; Molkentin, JD; Moll, UM; Muñoz-Pinedo, C; Nagata, S; Nuñez, G; Oberst, A; Oren, M; Overholtzer, M; Pagano, M; Panaretakis, T; Pasparakis, M; Penninger, JM; Pereira, DM; Pervaiz, S; Peter, ME; Piacentini, M; Pinton, P; Prehn, JHM; Puthalakath, H; Rabinovich, GA; Rehm, M; Rizzuto, R; Rodrigues, CMP; Rubinsztein, DC; Rudel, T; Ryan, KM; Sayan, E; Scorrano, L; Shao, F; Shi, Y; Silke, J; Simon, H-U; Sistigu, A; Stockwell, BR; Strasser, A; Szabadkai, G; Tait, SWG; Tang, D; Tavernarakis, N; Thorburn, A; Tsujimoto, Y; Turk, B; Vanden Berghe, T; Vandenabeele, P; Vander Heiden, MG; Villunger, A; Virgin, HW; Vousden, KH; Vucic, D; Wagner, EF; Walczak, H; Wallach, D; Wang, Y; Wells, JA; Wood, W; Yuan, J; Zakeri, Z; Zhivotovsky, B; Zitvogel, L; Melino, G; Kroemer, G (2018-03)
      Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the ...
    • Molecular mechanisms of human IRE1 activation through dimerization and ligand binding. 

      Joshi, A; Newbatt, Y; McAndrew, PC; Stubbs, M; Burke, R; Richards, MW; Bhatia, C; Caldwell, JJ; McHardy, T; Collins, I; Bayliss, R (2015-05)
      IRE1 transduces the unfolded protein response by splicing XBP1 through its C-terminal cytoplasmic kinase-RNase region. IRE1 autophosphorylation is coupled to RNase activity through formation of a back-to-back dimer, although ...
    • Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes? 

      Eason, K; Sadanandam, A (2016-09)
      Tumor heterogeneity is reflected and influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment. This heterogeneity has resulted in the stratification ...
    • Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. 

      Whittaker, SR; Barlow, C; Martin, MP; Mancusi, C; Wagner, S; Self, A; Barrie, E; Te Poele, R; Sharp, S; Brown, N; Wilson, S; Jackson, W; Fischer, PM; Clarke, PA; Walton, MI; McDonald, E; Blagg, J; Noble, M; Garrett, MD; Workman, P (2018-03)
      Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer. ...
    • Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. 

      Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; Yuan, L; Begum, R; Eltahir, Z; Wotherspoon, A; Montero-Fernandez, A; Teixeira Mendes, LS; Gonzalez de Castro, D; Wilson, SH; Proszek, P; To, YM; Hawkes, E; Roy, A; Cunningham, D; Rao, S; Watkins, D; Starling, N; Bowcock, AM; Chau, I (2017-09)
      This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ...
    • Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. 

      Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; Yuan, L; Begum, R; Eltahir, Z; Wotherspoon, A; Montero-Fernandez, A; Teixeira Mendes, LS; Gonzalez de Castro, D; Hulkki Wilson, S; Proszek, P; To, YM; Hawkes, E; Roy, A; Cunningham, D; Rao, S; Watkins, D; Starling, N; Bowcock, AM; Chau, I (2017-04-11)
      This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ...
    • Molecular radiotheragnostics in prostate cancer 

      Du, Y; Dizdarevic, S (Royal College of Physicians, 2017-10)
    • Molecular radiotheranostics for neuroendocrine tumours. 

      Navalkissoor, S; Flux, G; Bomanji, J (2017-10)
      This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus ...
    • Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. 

      Coakley, M; Garcia-Murillas, I; Turner, NC (2019-10)
      Advances in diagnosis and treatment have resulted in a high rate of survival for many patients with early-stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent ...
    • Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro 

      Bruno, L; Hoffmann, R; McBlane, F; Brown, J; Gupta, R; Joshi, C; Pearson, S; Seidl, T; Heyworth, C; Enver, T (2004-01)
      The molecular mechanisms governing self-renewal, differentiation, and lineage specification remain unknown. Transcriptional profiling is likely to provide insight into these processes but, as yet, has been confined to ...
    • Molecular similarity considerations in the licensing of orphan drugs. 

      Franco, P; Porta, N; Holliday, JD; Willett, P (2017-02)
      The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs (i.e., medicinal products that are designed ...
    • Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. 

      Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; Benson, C; van der Graaf, WT; Jones, RL (2017-01)
      Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated ...
    • The molecular underpinnings of prostate cancer: impacts on management and pathology practice. 

      Rodrigues, DN; Boysen, G; Sumanasuriya, S; Seed, G; Marzo, AMD; de Bono, J (2017-01)
      Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies are based largely on anatomical and pathological parameters. In the recent past, several DNA sequencing studies of primary and ...
    • Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. 

      Mackay, A; Burford, A; Molinari, V; Jones, DTW; Izquierdo, E; Brouwer-Visser, J; Giangaspero, F; Haberler, C; Pietsch, T; Jacques, TS; Figarella-Branger, D; Rodriguez, D; Morgan, PS; Raman, P; Waanders, AJ; Resnick, AC; Massimino, M; Garrè, ML; Smith, H; Capper, D; Pfister, SM; Würdinger, T; Tam, R; Garcia, J; Thakur, MD; Vassal, G; Grill, J; Jaspan, T; Varlet, P; Jones, C (2018-05)
      The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between ...
    • Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. 

      Lheureux, S; Denoyelle, C; Ohashi, PS; De Bono, JS; Mottaghy, FM (2017-08)
      Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the ...
    • Monitoring the ERSPC trial. 

      De Koning, HJ; Hakulinen, T; Moss, SM; Adolfsson, J; Smith, PH; Alexander, FE; ERSPC (2003-12)
    • Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI. 

      Robinson, SP; Boult, JKR; Vasudev, NS; Reynolds, AR (2017-08)
      Antiangiogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC). However, the ability of antiangiogenic drugs to delay tumor progression and extend survival is limited, due to either innate or acquired drug ...
    • Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth? 

      Morgan, VA; Parker, C; MacDonald, A; Thomas, K; deSouza, NM (2017-09)
      The purpose of this study was to measure longitudinal change in tumor volume of the dominant intraprostatic lesion and determine whether baseline apparent diffusion coefficient (ADC) and change in ADC are indicative of ...
    • Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1/2) are formed endogenously in intact cardiac myocytes and are enzymically active 

      Paterson, H (ELSEVIER SCIENCE INC, 2011-02)
      ERK1 and ERK2 (ERK1/2) are central to the regulation of cell division, growth and survival. They are activated by phosphorylation of the Thr- and the Tyr- residues in their Thr-Glu-Tyr activation loops. The dogma is that ...